Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Titel:
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Auteur:
Siena, Salvatore Di Bartolomeo, Maria Raghav, Kanwal Masuishi, Toshiki Loupakis, Fotios Kawakami, Hisato Yamaguchi, Kensei Nishina, Tomohiro Fakih, Marwan Elez, Elena Rodriguez, Javier Ciardiello, Fortunato Komatsu, Yoshito Esaki, Taito Chung, Ki Wainberg, Zev Sartore-Bianchi, Andrea Saxena, Kapil Yamamoto, Eriko Bako, Emarjola Okuda, Yasuyuki Shahidi, Javad Grothey, Axel Yoshino, Takayuki